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ABSTRACT 
 
Axillary sentinel lymph node biopsy plays an important role in breast cancer management 
in determining further surgical and medical treatment options. Intraoperative assessment of 
the sentinel lymph node might allow immediate axillary surgery, which would incur 
benefits to both the patient and healthcare trusts. A handheld Raman spectroscopy probe 
has already been shown to be a comparable option for intraoperative assessment through 
previous published and unpublished studies, delivering a sensitivity of up to 92% and 
specificity of up to 99%. 
This research aims to define further the role of the hand-held Raman spectroscopy probe as 
an accurate, rapid and non-destructive technique for intra-operative axillary node 
assessment, making it a strong competitor in the clinical market. It also looks to improve 
the sensitivity of the probe by altering the methodology used in previous studies. 
122 lymph node halves were collected intraoperatively from 37 patients diagnosed with 
breast cancer and spectra measured using a commercially available handheld Raman 
spectroscopy probe. Spectra were then fed into a specialist software programme and 
analysed using principal component fed linear discriminant analysis trained by 
histopathology results. 
A “2 group” training model defining the probe‟s ability to distinguish between benign and 
malignant tissue produced an overall performance of 86.4%, with a sensitivity of 71% and 
specificity of 91%. 
The results were not as impressive as previous studies. This was possibly due to a broken 
probe, leading to four different phases of measurements (original probe/failing 
probe/temporary replacement/mended probe). Secondly a smaller, less balanced data set, in 
terms of spectra per pathology group, was collected and there appeared to be more 
fluorescence in some of the data which may have originated from varying blue dye 
injection protocols. However, that said further research using a robust, high specification 
system may help establish its role as a reliable assessment tool  intraoperatively  as well as 
a non-invasive means of assessing lymph nodes in the initial assessment clinic. 
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CHAPTER 1 INTRODUCTION 
 
1.1  Breast Cancer in the UK 
Breast Cancer is the most common cancer in the UK. In 2008 alone, there were 48,034 new 
cases diagnosed, accounting for 31% of all cases of cancer in women (Office for National 
Statistics 2010). 
 
The disease itself is age-related. Nearly half of the women diagnosed are within the 50-69 
year old age group. However, of note, it is the second most commonly diagnosed cancer in 
women under 35. 
 
With respect to mortality, breast cancer is the second most common cause of cancer death 
in women following lung cancer.  Just over 10,000 women died from the disease in 
England in 2008 which is equivalent to a rate of 26 deaths per 100,000 women (Office for 
National Statistics 2010). 
 
However, although incidence rates for breast cancer increased by more than 85% between 
1971 and 2008, mortality rates fell by 33%. Survival rates are significantly higher than 
those for other major cancers in women. Five-year survival was 83% for women in England 
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diagnosed in 2003-07 and followed up to the end of 2008. In fact, almost 2/3 of women 
diagnosed with breast cancer survive beyond 20 years (Office for National Statistics 2010). 
 
These impressive figures are a result of both earlier detection through the national 
screening programme and improved management of the disease. 
 
1.2 Breast Cancer Management 
In 2009, the Association of Breast Surgery presented the basis of “gold standard” breast 
cancer management through a set of guidelines (Association of Breast Surgery 2009) to 
support these improvements. The guidelines are divided into a number of categories: 
1) Multidisciplinary care 
2) Diagnostics  
3) Treatment planning and patient communication 
4) Organisation of Breast Cancer Surgical Services 
5) Surgery for Invasive Breast Cancer  
6) Axillary Node Management in Invasive Breast cancer 
7) Surgical management of DCIS 
8) Surgery for LCIS 
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9) Breast Reconstruction 
10) Peri- and post-operative care 
11) Adjuvant treatment 
12) Clinical follow-up 
 
1.3 Management of axillary lymph nodes in breast cancer 
This research will be concentrating on axillary node management in invasive breast cancer. 
The guidelines above suggest that the presence of node metastases is the most powerful 
prognostic determinant in primary operable breast cancer. All patients in this group should 
therefore have axillary staging and treatment as appropriate. 
 
In some cases, pre-operative axillary node assessment with ultrasound and fine needle 
aspirate (FNA) can yield a diagnosis of involved nodes. These patients will either go 
straight to axillary clearance, retrieving at least 10 nodes, in their primary operation or will 
have axillary radiotherapy post-operatively. 
 
In most cases, however, sentinel node biopsy has become the standard approach for staging, 
providing accurate axillary assessment with good sensitivity and specificity rates. The 
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histological status of the sentinel node has been shown to reflect the overall status of the 
axilla in over 97% of cases (Veronesi et al 1997). 
 
Sentinel lymph node biopsy involves injection of blue dye and/or a radio-isotope into the 
ipsilateral breast to indicate the first few axillary nodes draining the breast. These are 
removed via a small axillary incision and sent for histopathological assessment. Any 
evidence of macrometastases or indeed micrometastases should point towards further 
axillary treatment in the form of radiotherapy or axillary clearance at a later date in addition 
to adjuvant systemic therapy.  
 
Unfortunately, both axillary radiotherapy and clearance leads to significant comorbidity. 
Symptoms include lymphoedema, reduced mobility and recurrent infections in the 
ipsilateral arm. Therefore it should only be performed if necessary to the patient. 
 
1.3.1 The future of axillary lymph node management 
In 2011, a randomised trial of axillary node dissection in women with clinical T1-2 breast 
cancer with positive sentinel nodes was carried out in the United States over 115 treatment 
centres (Giuliano et al 2011). The results demonstrated that among this patient group breast 
conservation surgery and systemic therapy with sentinel lymph node dissection alone 
inferred no less survival benefit than those undergoing complete axillary clearance. It 
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should be emphasised that these results apply only to patients meeting the very specific 
criteria of the study. The study was also restricted to 891 of the planned 1900 patients. So 
far, clinical practice in the UK has remained unchanged but the potential effects it could 
have on surgical guidelines, if further evidence is documented, is enormous. 
 
1.4 Intraoperative axillary node staging 
The introduction of axillary sentinel node biopsy as a standard practice has welcomed the 
challenge of intra-operative staging of the axillary nodes. Traditionally, the sentinel nodes 
excised during the initial operation for the primary breast tumour are sent away for 
histological assessment. 
 
Unfortunately, this requires the patient to wait before finding out if a full clearance or 
radiotherapy is needed. Psychological stress,  delay in any adjuvant treatment, and 
increased cost implications of further surgery and hospital admission are all significant 
concerns as a result (Layfield et al 2011).  
 
Intra-operative staging would offer the patient definitive treatment of the axilla in the initial 
operation, thus potentially resolving these issues. However, in order to be a gold standard 
treatment, both specificity and sensitivity must remain high. False positive results would 
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lead to unnecessary axillary clearance, resulting in significant comorbidity as outlined 
above. Meanwhile, false negative results, whilst not deleterious to the patient, would leave 
us with a system where results have to be double-checked, thus adding to costs. 
 
There are a number of techniques being studied to look at intraoperative lymph node 
assessment. 
 
1.4.1 Histological techniques 
Intraoperative frozen section analysis of sentinel lymph node biopsies is currently the most 
commonly used technique. Its reported sensitivity ranges from 57% to 74% whilst 
specificity ranges between 99-100% (Layfield et al 2011). 
 
Unfortunately, the process is expensive, time poor and labour intensive. It relies on a 
dedicated histopathologist being available. Frozen sections themselves can carry freeze 
artifacts and the histological morphology is poorer than paraffin sections which could 
attribute to lower sensitivities. Furthermore, the tissue, once frozen, is lost and this can lead 
to concerns about missing micrometastases and understaging lymph nodes. 
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1.4.2 Cytological techniques 
Touch imprint cytology involves the cut surface of a sentinel lymph node being pressed or 
scraped against a glass slide. This is subsequently stained and examined under a 
microscope by a histopathologist. A meta-analysis of 31 articles by Tew (Tew et al 2005) 
estimated sensitivity levels at 63% and specificity levels at 98-99%. Leaving 
micrometastases out of the equation the sensitivity rises to 81% for macrometastases alone. 
This is due to the smaller amount of cellular tissue examined and the size of 
micrometastases themselves. 
 
Further studies have found that the sensitivity of imprint cytology also varied according to 
the type of invasive breast cancer (Cox et al 2005). Invasive lobular cancer has cells which 
are poorly cohesive and tend to resemble lymphoid cells. Sensitivity for lobular carcinoma 
metastases was therefore 38.7% compared with 55.5% for ductal type. 
 
Whilst cytology is certainly faster and cheaper than frozen section, it still requires the 
presence of a histopathologist. Its sensitivities may well be improved by increased sampling 
as well as the use of immunocytochemistry. The latter has been incorporated in various 
studies and advocated as a means of improving diagnosis in invasive lobular carcinoma 
(Leikola et al 2005) as well as detection of micrometastases (Salem et al 2006).  Despite 
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increased sampling and immunostaining, tissue is preserved for further histological 
assessment post-operatively. 
 
1.4.3 Molecular techniques 
Molecular techniques to assess the sentinel lymph node look for the presence of marker 
genetic material. In this way, the techniques are essentially assessing the whole lymph node 
rather than just sections, potentially removing the danger of sampling error.  
 
Quantitative Reverse Transcriptase-polymerase chain reaction (qRT-PCR) differentiates 
between high levels of marker mRNA in tumour cells and the lower “expected” levels in 
non-cancerous tissue. Unfortunately there is no single gene yet identified which is 
expressed universally in cancer cells. 
 
In 2005, Backus therefore used a combination of widely expressed markers MGB1 and CK-
19. They managed to achieve sensitivity of 91% and specificity of 97% in laboratory 
conditions (Backus et al 2005). 
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The first commercially available assay based on this technology and using these two 
markers was the Genesearch
TM
 Breast Lymph Node (BLN) Assay (Veridex, Warren, New 
Jersey, USA). 
 
Blumencranz (Blumencranz et al 2007) carried out a prospective study of 416 patients 
where positive or negative BLN Assay results, generated from fresh 2-mm node slabs, were 
compared with results from conventional histological evaluation of adjacent fixed tissue 
slabs. The assay detected 98% of metastases greater than 2 mm and 88% of metastasis 
greater than 0.2 mm. Micrometastases were less frequently detected (57%) and assay 
positive results in nodes found negative by histology were rare (4%). This concluded that 
the BLN Assay was properly calibrated for use as a stand- alone intraoperative molecular 
test. 
 
However, despite this, the product was withdrawn from the market due to low demand. The 
Wall Street Journal attributed this to high set up costs, concerns about lower specificity 
rates than frozen section analysis as well as logistical difficulties (Loftus et al 2010). 
 
The reduced specificity could be a result of contamination from the primary breast tissue 
during excision. Advocates of the technique have also argued that the discrepancies in 
specificity may result from the inability to directly compare histology of the same tissue 
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due to homogenisation of the tissue for PCR. The metastatic deposit may have been entirely 
within the sample taken. Indeed, further analysis of lysate from BLN-positive and 
histology-negative lymph nodes with additional molecular markers have supported the 
presence of metastatic material in up to 76% of these samples (Blumencranz et al 2007). 
 
An alternative to qRT-PCR is Reverse Transcriptase loop-mediated isothermal 
amplification (RT-LAMP). Similarly, it uses reverse transcriptase to convert mRNA to 
cDNA. However, it then uses 6 primers specific to that cDNA target to cause looping of the 
DNA during amplification which results in the release of a by-product, pyrophosphate. 
Pyrophosphate binds to magnesium causing precipitation. The extent of precipitation is 
used to quantify the amount of target gene present. 
 
Studies using this technique have described specificities between 89 to 97.1% with 
sensitivities between 92.9 to 98.1% (Layfield et al 2011). 
 
1.4.4 Raman Spectroscopy 
Recent studies using a hand held Raman spectroscopy probe have proposed a further tool 
which is a potentially efficient method of diagnosing metastases in axillary lymph nodes. 
Its properties are comparable to those above and this will be explored further. The theory 
behind this technique will be described in Chapter 3 and 4. 
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1.5 Thesis Objectives 
This study aims to address the following proposals in relation to Raman Spectroscopy as a 
means of accurately assessing lymph nodes intraoperatively: 
 
 Use of a hand-held Raman Spectroscopy probe in theatre is an accurate, rapid and 
non-destructive technique for intraoperative axillary node assessment. 
 
 The sensitivity of the Raman Spectroscopy probe is improved by recording spectra 
at more than one site on the lymph node. 
 
 The Raman Spectroscopy probe has characteristics comparable to histopathology 
such that it is a strong competitor in the clinical market for intraoperative lymph 
node assessment.  
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CHAPTER 2 THE BREAST AND BREAST CANCER 
 
2.1 The Breast and Axilla 
2.1.1 Anatomy  
The breasts, also known as mammary glands, are considered to be highly modified apocrine 
sweat glands. In both sexes, the breasts follow a similar developmental course until 
puberty. At this stage the female breasts develop under the influence of pituitary, ovarian 
and other hormones. From puberty to the menopause, the breast tissue undergoes cyclical 
changes controlled by hormones of the ovarian cycle. After menopause, the breasts undergo 
gradual atrophy and involution. 
 
The breast consists of glandular tissue and fat embedded in the superficial fascia of the 
anterior chest wall. Although the size and shape of the female breast can vary, its base is 
constant and overlies three muscles – pectoralis major, serratus anterior and rectus 
abdominis. In the adult female, the base is roughly circular and extends between the second 
and sixth ribs. Medially it overlies the lateral border of the sternum. Part of the breast also 
extends upwards and laterally, reaching the anterior fold of the axilla, forming the axillary 
tail. 
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The breast‟s structural architecture is created by the fatty tissue divided by Cooper’s 
suspensary ligaments. Opening on to the surface of the nipple are 20 or so lactiferous 
ducts.  Each of these ducts drains milk from different segments (lobes) of the breast.  At the 
end of each duct are a number of lobules that consist of multiple acini. These are the milk-
producing glands, which are hormone dependent. Terminal ducts connect the acini to the 
mammary ducts. (Figure 2.1) 
Figure 2.1 Breast Anatomy (www.breastdiagnostic.com; 03/09/2012) 
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The axilla (Figure 2.2) is the space between the root of the upper limb and the chest wall. It 
is traversed by the main vessels and nerves which pass between the upper limb and root of 
neck. Its shape can be thought of as a pyramid with a narrow apex superiorly and a broad 
base with three walls. The structures at risk of iatrogenic damage during a surgical axillary 
dissection are: 
 Axillary vein 
 Long thoracic nerve – supplies serratus anterior 
 Thoracodorsal nerve – supplies latissimus dorsi 
 Intercostal brachial nerve – supplies sensation for inferior aspect of the arm 
and posterior aspect of axilla itself 
Figure 2.2  The Axilla (www.breastdiseases.com; 03/09/2012 ) 
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2.1.2 Blood Supply 
The breast receives blood from branches of arteries supplying the deeper structures of the 
chest wall (internal thoracic artery and the second, third and fourth intercostal arteries) as 
well as the lateral thoracic and thoracoacromial arteries, which are branches of the 
axillary artery. 
 
2.1.3 Lymph Drainage 
The lymphatic system is part of the body‟s immune system that carries lymph from tissues 
back towards the heart and ultimately back into circulation via a network of conduits called 
lymphatic vessels. The system has a number of functions which include removal of 
interstitial fluid from tissues; absorption and transport of fats from bloodstream (chyle); 
transport of white blood cells to and from lymph nodes; assisting in the body‟s immune 
response when stimulated.  
 
Due to its proximity to many tissues within the body, it is also responsible for carrying 
cancer cells away from a primary site of neoplastic growth, a process called metastasis. 
 
The breast‟s lymphatic system drains into two anatomical sets of lymph nodes - 75% of 
lymph goes to axillary nodes whilst the rest goes to the internal mammary nodes near the 
centre of the chest. (Figure 2.3) 
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Figure 2.3 Lymphatic Drainage of the breast (www.breastdiseases.com; 03/09/2012) 
 
 
 
2.2  Lymph Nodes 
Lymph nodes tend to occur in groups. The main ones are found where the lymphatics 
converge to form larger trunks – neck; axillae (as above); groins; lung hila and para-aortic 
areas.  
 
The cells making up the lymph node can be divided into three functional types (Burkitt 
1993): 
 Lymphoid cells – Lymphocytes of all types and their derivatives. 
 Immunological accessory cells – macrophages and other phagocytic antigen 
processing and presenting cells. 
 Stromal cells – lymphatic and vascular endothelial cells and fibroblasts 
which are responsible for the structural framework of the lymph node. 
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Macroscopically, a lymph node is a small bean-shaped organ. Whilst inactive, it is only a 
few millimetres long but this increases in size when stimulated to mount an immunological 
response. 
 
Microscopically, the outer part of the lymph node is cell-rich and is known as the cortex. 
The central area is less cellular and is called the medulla. Encapsulating the lymph node is 
dense collagenous tissue. From here trabeculae extend into the substance of the node. 
Afferent lymphatic vessels branch outside the node then pierce this capsule to drain lymph 
into a narrow space called the subcapsular sinus which extends around and beneath the 
surface. From here, cortical sinuses pass towards the medulla through the cortex. 
Within the medulla itself, the medullary sinuses, a network of broad interconnected 
lymphatic channels converge on the hilum. Lymph drains from here into the efferent 
lymphatic vessels (Figure 2.4). 
Figure 2.4  Lymph Node (Burkitt 1993) 
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2.3 Breast Cancer 
Breast cancer originates from breast tissue, usually either in the ducts or lobules. It can be 
classified according to its histological types as well as the site at which it originates. 
 
2.3.1 Carcinoma-in-situ 
The term carcinoma-in-situ describes pre-invasive neoplastic cell changes confined within 
either the ducts or lobules of the breast. Due to its in situ nature, there is no risk of 
metastatic behaviour. It is subclassified into ductal (DCIS) and lobular (LCIS) carcinoma-
in-situ according to the site of the cell changes. 
 
DCIS is a malignant, clonal proliferation of cells growing within the basement membrane-
bound structures of the breast and with no evidence of invasion into surrounding stroma. It 
is graded histopathologically according to cell differentiation. The grade is related to the 
likelihood of progression to invasive carcinoma and the rapidity with which this is likely to 
occur. 
 
In comparison, LCIS is not a premalignant lesion. It is an abnormal pathology which 
identifies those women at a higher risk of subsequently developing invasive breast cancer. 
In fact, the subsequent cancers that do occur are more likely to be of ductal origin.   
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2.3.2 Invasive Ductal Breast Cancer 
Invasive ductal breast cancer (IDC) is the most common type of breast cancer and makes 
up 70 to 80% of cases. The malignant cancer cells penetrate the basement membrane of the 
ductal wall and invade the surrounding stroma. This allows potential for metastatic spread 
via the bloodstream or lymphatics. 
 
A common clinical sign of IDC is a hard palpable breast mass. This results from a 
fibroblastic response to the invasion of tumour cells. Dimpling of the skin over the breast 
tissue, nipple inversion or retraction may also occur due to tumour infiltration of 
surrounding structures and traction on the suspensory ligaments. 
 
Tumour cells can be identified histologically as they are much larger than normal epithelial 
cells. They can form a number of characteristic patterns within dense stroma. Grading of 
the tumour is determined by its differentiation from well differentiated tumours, with a 
typical glandular formation, to poorly differentiated tumours with solid sheets of 
pleomorphic cells. 
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2.3.3 Invasive Lobular Breast Cancer 
Invasive lobular carcinoma (ILC) makes up 10% of breast cancers and is thus the second 
most common type found in the population. It is often found in breast tissue also containing 
IDC. It has a tendency to occur in both breasts as well as having a multicentric pattern. 
 
Unlike IDC, clinical presentation is not always as obvious due to the variation of the 
stromal reaction to tumour invasion. 
 
Histologically, its cells are in fact a similar size to normal epithelium and rather than form a 
variety of patterns, tumour cells either infiltrate the stroma as individual rows (Indian file) 
or form targetoid lesions. Very occasionally, the tumour might have features of both ductal 
and lobular carcinoma. 
 
2.3.4 Other invasive breast carcinomas 
Less common types of invasive breast cancer include medullary, mucinous, tubular and 
cribriform carcinoma. 
 
Medullary carcinoma accounts for less than 5% of breast cancers. Similar to ILC, the 
stromal reaction might be minimal, making it difficult to diagnose clinically. Histologically 
there is evidence of haemorrhage and necrosis among the cells. The cells themselves have 
large nuclei of various shapes and appear in solid sheets which form a syncytium. 
Lymphocytes and plasma cells gather closely around these sheets. 
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Mucinous carcinoma makes up less than 5% of breast cancers also. Clinically it presents as 
a soft gelatinous mass. It can present on its own or in combination with other tumour types. 
The tumour is made up of isolated tumour cells (ITC) in pools of extracellular mucin as 
well as forming the occasional glandular structure. 
 
Tubular carcinoma is found in less than 2% of breast carcinomas. Histologically it forms 
small pleomorphic gland randomly arranged. Cribriform carcinoma also is a rare form of 
breast cancer and is identifiable by its “sieve-like” pattern of growth. Both of these are 
again seen mixed with other tumour types or as individual cancers. The latter forms have a 
much lower chance of lymph node metastases (up to 10%). 
 
2.3.5 Lymph node metastases 
As explained earlier in this chapter, the axillary lymph nodes are the primary lymphatic 
filter for the breast and therefore the first to be involved in metastatic breast carcinoma. The 
“sentinel” lymph node, which is usually the largest lymph node in the axilla, is considered 
the first to receive the lymph drained from the breast and thus the most likely to harbor a 
metastasis. Most metastases appear to infiltrate the lymph node in the direction of 
lymphatic flow. Thus the first metastases would be found in the subcapsular sinus before 
penetrating towards deeper sinuses and finally invading the parenchyma. 
 
The microscopic patterns of lymph node metastases tend to reflect the histological types of 
the primary breast tumour (Sharkey et al 1985). For example, in the case of IDC, the lymph 
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node metastases generally reproduce the nests and cords, as described above, with variable 
formation of duct-like spaces of the original tumour. (Figure 2.5) 
 
Figure 2.5 Metastatic ductal carcinoma with large aggregates of tumour cells plugging the lymph 
node sinuses (Haematoxylin, Phloxine and saffron stain) (Ioachim HL 2002)
 
 
 
The cells themselves vary from cuboidal and monomorphic to large and highly 
pleomorphic with frequent mitoses. (Figure 2.6) Reaction to the invading carcinoma can 
cause enlarged follicles with reactive germinal centres, excessive histiocytosis, granuloma 
formation or desmoplasia. Thick bands of collagen might also form which can obliterate the 
entire parenchyma. 
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Figure 2.6 Metastatic ductal carcinoma forming rudimentary gland structures and highly 
pleomorphic tumour cells with large nuclear masses. (Haematoxylin, Phloxine and saffron stain) 
(Ioachim HL 2002) 
 
 
Recognition of lobular carcinoma metastases is not as straight forward. These metastases 
are distributed in the sinuses, sometimes deep down in the cortex or even the medulla 
without initial involvement of the marginal sinuses. When the metastases are recent, they 
only consist of single cells or tiny clusters which are difficult to identify and can be 
confused with histiocytes and endothelial cells (Figure 2.7). Focal signet ring 
differentiation is also common in lobular carcinoma metastases (Ioachim HL 2002). 
 
 
 
24 
 
Figure 2.7 Metastatic lobular carcinoma with single tumour cells surrounding an involuted 
lymphoid follicle. (Haematoxylin, Phloxine and saffron stain) (Ioachim HL 2002) 
 
Histopathological analysis of lymph node metastases differentiates between 
micrometastases and macrometastases. The former describes a tumour deposit between 
0.2mm and 2mm; the latter describes those deposits greater then 2mm in size. Those cells 
or clusters of cells less than 0.2mm in size are referred to as Isolated Tumour Cells (ITC). 
 
2.3.6 Staging of breast cancer 
The most popular means of staging breast cancer is the American Joint Committee on 
Cancer (AJCC) TNM classification system. This system describes the extent of cancer in 
the body. T describes the size of the tumour and invasion of surrounding tissue planes; N 
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describes regional lymph nodes that are found to be involved; M describes the presence of 
distant metastases. 
 
 The stage of a breast cancer can be based on clinical information (i.e. physical 
examination, biopsy and imaging) or, more accurately, on the pathological information 
following surgery. A summary of the TNM classification system for breast derived from 
the AJCC cancer staging manual (Edge SB 2010) is found in Appendix A. 
 
2.3.7 Prognostic outcome 
The Nottingham Prognostic Index was created in 1982 following a multiple-regression 
analysis of prognostic factors and survival in a series of 387 patients with primary breast 
cancer (Haybittle et al 1982). The score was based on lymph node stage, tumour size and 
pathological grade.  
 
 Lymph Node Stage:  
o Negative lymph nodes have the most favourable prognosis.  
o Involvement of 4+ lymph nodes has the worst outcome. 
 
 Tumour Size: 
o The most favourable prognosis is seen in those tumours < 2cm in size. 
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 Grade:  
o Grading is determined by the amount of nuclear pleomorphism, mitotic 
extent and the number of well formed tubules. Higher grades of 
differentiation have a least favourable outcome. 
 
Histological type is also important in considering prognosis. IDC and ILC have the worst 
prognosis.  
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CHAPTER 3 VIBRATIONAL SPECTROSCOPY 
 
3.1 Definition 
Spectroscopy is the measure of the interaction between radiated energy and matter. 
Vibrational spectroscopy, which incorporates infra-red (IR) and Raman spectroscopy, is an 
analysis of the spectra produced by the vibrational modes of molecular bonds. It is 
therefore reflective of a molecule‟s structure and can thus be used to detect it.  
 
Molecular vibrations can be excited via two physical mechanisms: the absorption of light 
quanta and the inelastic scattering of photons. Direct absorption of photons is achieved by 
irradiation of molecules with polychromatic light as in IR spectroscopy. Meanwhile, the 
scattering mechanism for exciting molecular vibrations requires monochromatic irradiation 
as seen in Raman spectroscopy. (Siebert et al 2008) 
 
Whilst it is important to acknowledge the role of IR spectroscopy this study will 
concentrate on Raman spectroscopy.  
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3.2 Scattering of light 
Usually, when light interacts with matter, it does not gain or lose energy. At a molecular 
level, a photon is essentially interacting with a substance molecule, causing polarisation of 
its electron cloud. This raises its virtual energy state before it returns to normal, releasing a 
photon. The energy released in this photon is the same as the incident photon. The 
wavelength therefore remains constant.  
 
The photon released moves in any direction – it „scatters‟. This complete process is called 
Rayleigh scattering.  
 
Raman scattering, on the other hand, is an inelastic process whereby the light photons 
either lose or gain energy causing a change in wavelength. This is related to a molecule‟s 
vibrational modes determined by its bonds. (Figure 3.1) 
 
If the molecule moves from a ground state to virtual state then back to a higher energy level 
(its vibrational state) the emitted photon has less energy – Stokes Effect. 
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If the molecule starts from a higher energy level or vibrational state when it is excited, then 
moves back to its ground state after reaching its virtual state, the photon emitted has gained 
energy – Anti-Stokes Effect. 
Figure 3.1 Energy level diagram demonstrating the differences between Rayleigh and Raman 
scattering of light 
 
 
Only around 1 in 10
7 
photons undergo Raman Stokes scattering whilst significantly less 
undergo Anti-Stokes. These photons are swamped by Rayleigh scattered photons. Modern 
spectrometers have therefore been designed and developed with filters that reject elastically 
scattered light. 
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3.3 Vibrational Modes 
A molecule is an electrically charged neutral group of atoms held together as a single unit 
by electromagnetic forces resulting from the behaviour of their surrounding electron orbits. 
The vibrational mode of a molecule describes the relative positions of nuclei and electrons. 
 
For a diatomic molecule, there is only one mode of vibration, the bond stretch. (Figure 3.2) 
Figure 3.2 Bond stretch in a diatomic molecule 
 
 
 
However, in molecules made up of more than two atoms, there are several modes of 
vibration owing to the various changes in bond lengths and angles (Figure 3.3).  
 
 
 
  
  
Diatomic Molecule   
e.g. Hydrogen, H2 
Bond 
Stretch 
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Figure 3.3 Modes of vibration in a polyatomic molecule 
 
 
 
A normal mode for a specific molecule describes an independent, synchronous motion of 
atoms or groups of atoms that may be excited without leading to the excitation of any other 
normal mode and without involving rotation of the molecule (Atkins et al 2010). 
 
The total number of normal vibrational modes of a linear polyatomic molecule can be 
calculated by the equation 3N-5 where N is the number of atoms within the molecule. For a 
non-linear polyatomic molecule, as shown in Figure 3.3, the equation is 3N-6.  
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Different vibrational modes have different energy values. Rotational modes also exist but 
do not contain as much energy as vibrational modes. 
 
3.4  Raman Spectroscopy of vibrational modes 
Raman spectroscopy is used to elucidate the energy changes produced by the transition 
between vibrational modes in the target molecule after illumination by incident light 
(Raman Shift). Analysis of the spectra can therefore help us to identify the specific bonds 
involved allowing us to determine the molecule‟s structural configuration. 
 
However, for a molecule to be Raman active, the normal modes of vibration must be 
accompanied by a changing polarizability (Siebert et al 2008). Significant changes in 
polarizability are noted in electron-rich groups such as: 
C=O C=N C=C  
Those molecules containing these bonds will demonstrate intense peaks on their spectra. 
This enables recognition of particular molecules, e.g. collagen, lipid, actin, nucleic acid, 
protein, carbohydrate as a result of our pre-existing knowledge of their chemical structure. 
 
Vibrational modes which leave polarizability unchanged are Raman inactive and therefore 
do not contribute to the Raman spectra. 
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3.5 Infra-Red Spectroscopy 
Molecular vibrations can be also be excited by the absorption of light (Herzberg et al 1945) 
When infrared incident light is shone on a tissue, the molecules tend to absorb the photons. 
This also results in changes in the vibrational modes. However, the change results in an 
alteration in the dipole moment of the molecule. This gives the molecule the properties of 
two particles with opposite charges separated by a specific distance.  
 
Certain molecules, such as water are more IR active than Raman active. Whilst the use of 
IR spectroscopy is therefore limited in vivo for this very reason, it can be used ex vivo to 
both validate and complement Raman. 
 
3.6 Fluorescence 
A common problem in studying Raman spectra is fluorescence. This occurs when the 
incident light, especially at the UV and visible end of the spectrum is absorbed by the tissue 
promoting an electron to an excited state, resulting in the dissipation of heat and the 
emission of a photon with a longer wavelength. To minimise this effect, Near-infrared 
(NIR) incident light with a longer wavelength is used as this is less easily absorbed, thereby 
minimising fluorescence. 
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CHAPTER 4 APPLICATION OF RAMAN SPECTROSCOPY 
 
4.1  A Historical Overview 
In 1923, Adolf Smekal, an Austrian physicist, first predicted the existence of inelastic 
scattering of light (Opel et al 2002). Five years later, in 1928, C.V Raman carried out a 
series of experiments in his Calcutta laboratories that demonstrated its existence (Raman et 
al 1928). He found that light scattered by a liquid, such as benzene, contains sidebands in 
pairs symmetrically disposed around the frequency of incident light. The shifts were 
identical to the frequencies of some of the IR vibrational spectral lines of the liquid. 
Landsberg and Mandelstam observed similar effects in solids such as quartz (Opel et al 
2002). The concept was named the Raman effect and earned Raman himself a Nobel Prize 
in 1930. 
 
In the next 75 years, Raman spectroscopy became an important tool for studying 
elementary excitations in gases, liquids and solids. However, progress was initially slow 
due to the limited sources of radiation and technology for detection and analysis of the 
spectra.  
 
With the introduction of the working laser in 1960 (Maiman et al 1960) the charged 
coupling device in 1970 (Boyle et al 1970) and the development and application of Fourier 
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Transform techniques to present the detected photon energy as spectra (McClure et al 
1988), studies into the use of Raman spectroscopy were renewed with increased 
enthusiasm. 
 
4.2 Application of Raman Spectroscopy 
In the past few years, the extent of progress in instrumentation for Raman spectroscopy has 
improved such that robust, high quality data is now possible. The main developments are 
noted to be: 
 In vivo probes for biopsy targeting; 
 Histopathology tools; 
 Deep Raman tools for in vivo analysis in solid organs; 
 Enhancing signal production.  
 
These significant milestones are described in detail by Kendall (Kendall et al 2009). 
Initially, work was focussed on differentiating normal tissue and advanced cancers. 
However, with developing technology and complex analytical methods, we have been able 
to move towards the diagnosis of neoplastic change at much earlier stages. 
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4.2.1 Technique of tissue Raman Spectroscopy 
The technique of Raman Spectroscopy involves the illumination of a tissue sample with 
monochromatic radiation usually at a near-infrared wavelength. The inelastically scattered 
photons are then measured, thereby probing the vibrational and rotational modes of the 
molecules within the sample.  
 
Whilst Raman had to use sunlight focused through a telescope to acquire sufficient 
intensity for the scattered signal, modern spectrometers use lasers at a single wavelength 
along with more sensitive detectors to obtain better results. CCDs have also been 
incorporated to enable the measurement of a whole spectrum at once.  
 
Furthermore, the main difficulty in Raman spectroscopy has been found to be the 
prevention of overlap of the Raman signal by stray light from Rayleigh scattering. 
Interference notch filters are frequently employed, which filter out wavelengths within 
approximately 100 cm
-1
 of the laser wavelength. Holographic diffraction gratings might 
also be incorporated which result in much less stray light than ruled gratings (University of 
Cambridge 2007). Figure 4.1 demonstrates a simplified diagram of a Raman 
Spectrometer‟s operation.  
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Figure 4.1 Simplified Raman Spectrometer (University of Cambridge 2007) 
 
 
The subsequent spectrum produced is a plot of the inelastically scattered photon intensity as 
a function of the energy difference between the incident and scattered light (Raman Shift). 
 
Figure 4.2 is an example of Raman shift demonstrated by axillary lymph node spectra 
which are positive for metastases compared with negative lymph nodes (Horsnell et al 
2010). 
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Figure 4.2  Mean normalised spectra of metastatic nodes versus non-metastatic nodes 
(Horsnell et al 2010) 
  
The intensity of individual peaks is proportional to the concentration of the molecular 
constituent giving rise to that peak. A database of peak positions and assignments has been 
created from several studies in order to aid in detection of various molecules. (Kendall et al 
2002). 
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Multivariate data analysis methods might be used with Raman Spectroscopy to help 
classify tissue samples based on their biochemical makeup. Principal component analysis 
(PCA) is an unsupervised data reduction technique which describes the major sources of 
independent variation in the data. The data is fed into a supervised classification system 
such as linear discriminant analysis (LDA) using factual information about the samples, 
such as histopathological analysis. These techniques of spectral analysis will be described 
later on in Chapter 5. 
 
4.2.2 Raman spectroscopy probes 
Fibre optic probe technology has offered the opportunity to both illuminate and collect 
Raman spectra in vivo. However initial studies showed that fibres can generate Raman 
signals themselves, as demonstrated by Shim (Shim et al 1999). Elastically scattered light 
returning along the collection fibres themselves may also create further background signal.  
 
Thus probe designs had to be able to prevent these interference signals. For example, 
holographic and metal oxide edge filters have been investigated for their ability to reject 
Rayleigh scattered light. (Kendall et al 2009). More recently, in vivo probes coupled to a 
spectrometer have been introduced as a means of real-time measurement and analysis. It is 
this design on which this research is based.  
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The majority of work in this research group has looked at the use of in vivo assessment of 
oesophageal tissue to identify the subtle pre-malignant changes related to carcinogenesis 
(Kendall et al 2011). Raman probes offered non-invasive optical biopsy with the benefit of 
reduced number of random normal biopsies being collected and processed. Furthermore, it 
could assess resection margins of tissue intra-operatively. This would reduce the need for 
further repeat procedures which are currently required when histological assessment, 
performed days later, demonstrates inadequate resection.  
Other areas of research have included the use of probes for in vivo assessment of the cervix 
(Liu et al 2011), head and neck (Harris et al 2010), colon (Molckovsky et al 2003) and 
bladder (Crow et al 2005). The use of probes for assessing breast disease and lymph nodes 
will be further discussed later on in this chapter. 
 
4.3 Clinical need for Raman spectroscopy 
Cancer diagnostics plays a pivotal role both as an important tool for early detection and 
through its role in cancer management. 
 
Early detection of cancer has been shown to improve the chances of successful treatment 
and decrease mortality rates (UK Trial of Early Detection of Breast Cancer Group. 1999) 
Ongoing research has demonstrated that many cancers develop through pre-malignant 
stages. Eradication of these abnormal cells prior to systemic invasion will prevent 
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development of the cancer further. This type of disease prevention not only benefits the 
patient but also healthcare providers, particularly in a climate where finances are limited. 
The clinical need for techniques that can identify or detect these pre-malignant biochemical 
changes is thus considerable.  
 
It should be noted, however, that the danger of this technology is overtreatment. It is 
therefore important to have a clear understanding of progression and the natural history of 
the disease in question.  
 
Diagnostics as part of cancer management is equally important. A quick, non-destructive, 
efficient and cheap tool that is as non-invasive as possible is required.   
 
Currently, histopathology is the “gold standard” for most cancer diagnostics. However, this 
method is invasive, requiring removal of tissue biopsies often randomly and unnecessarily.  
Tissue fixation, sectioning and staining follow which can be expensive and time-
consuming. Analysis is very much subjective and is often associated with inter-observer 
disagreement (Montgomery et al 2001). 
 
Recent advances in Raman spectroscopy have promoted it to a level at which it might be 
seen as a comparable diagnostic tool. Ex vivo studies have demonstrated its potential in 
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aiding the histopathologists in the identification and classification of subtle biochemical 
changes related to carcinogenesis rather than complete dependence on morphology. Raman 
spectroscopy can provide rapid, high resolution, non-destructive data which is not 
influenced by the subjectivity of histopathology. Spectral classification models are 
currently under development (Shetty et al 2006) which are trying to understand 
biochemical changes using a variety of multivariate techniques such as Principal 
Component Analysis leading to Linear Discriminant Analysis. PCA is non-supervised 
which explores the variance in data. LDA correlates these changes with the gold standard 
of histopathology (Horsnell et al 2010). The decision is therefore not itself based on the 
subjectivenes of morphology, making it advantageous. There are other multivariate 
techniques also such as Partial Least Squares Discriminant Analysis which can  
demonstrate causes of discrimination, using loadings and weights, thus giving it a unique 
role in exploratory data analysis. 
 
In vivo, Raman spectroscopy offers the potential for “optical biopsy” with important 
clinical benefits. Excisional tissue biopsy carries risks of bleeding and perforation of a 
viscus as well as removal of normal tissue unnecessarily. In vivo Raman spectroscopy 
would obviate the need for this, thus reducing trauma to the patient, reducing the clinician 
workload, and reducing secondary repeat procedures. It would also decrease the rate of re-
excisions of areas of dysplasia or malignancy by accurately defining resection margins 
(Hanlon et al 2000). 
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4.4.1 Raman spectroscopy in breast disease 
Raman Spectroscopy has the potential to impact breast cancer diagnostics in a number of 
ways including the in vivo detection and identification of abnormal lesions as well as by 
means of a histopathological classification tool which may provide a measure of prognostic 
biochemical changes.  
 
Fourier Transform Raman was first used to discriminate breast cancer tissue in 1991 
(Alfano et al 1991). More recent studies, using 830 nm excitation and dispersion 
spectrometers, showed discrimination of normal, benign and malignant breast tissue 
(Shafer-Peltier et al 2002), (Manoharan et al 1998). Raman mapping of breast duct 
epithelia identified different cellular compounds using PCA and k-means clustering 
(Kneipp et al 2003) such as cytoplasm and nuclei. 
 
Calcifications detected by mammography during national screening programmes can be an 
indicator of a malignant breast lesion. However, mammography alone does not reliably 
classify calcifications as benign or malignant. In fact, only up to 25% of these lesions are 
found to be malignant on core biopsy (Haka et al 2005). Raman spectroscopy has been 
shown to distinguish between the different chemical make-up of benign and malignant 
calcifications (Haka et al 2002). It has also highlighted the potential to probe deep breast 
calcifications in vivo by means of  Kerr-gated spectroscopy (Baker et al 2007). Although 
this form of technology is not necessarily appropriate in vivo due to safety and practicality, 
other deep Raman techniques have stemmed from it as a result at the Rutherford Appleton 
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Laboratory, UK. Spatially offset Raman spectroscopy (SORS) has demonstrated 
discrimination between different calcification types at 8.7 mm depth. This finding has lead 
to the possibility of detecting lower calcification concentrations as well as those at greater 
depths (Stone et al 2007). Transmission Raman spectroscopy has enabled signal recovery 
and identification of calcifications at depths of 27 mm and at calcification volume densities 
within physiological levels (Stone et al 2008). 
 
Recently, studies on mammary tumours in mice have correctly identified all normal and 
mastitis Raman spectra and 91% of tumour spectra (Kast et al 2008). Normal tissue 
surrounding the tumour, given the term “tumour bed”, was interrogated as a separate data 
group. Suspicious atypical cells were discovered and were found to be different from 
normal, tumour, and mastitis tissue, proposing a pre-neoplastic process as might be 
expected.  A further study demonstrated 99% of non-tumour tissue and 95% of tumours 
induced in mice were correctly classified by Raman spectroscopy (Thakur et al 2007). 
 
A Raman study to diagnose benign and malignant lesions in human breast tissue 
differentiated between invasive carcinoma, fibrocystic change, fibroadenoma, and normal 
tissue (Haka et al 2005).  The diagnostic algorithm used in the study yielded a sensitivity of 
94%, specificity of 96% and an overall accuracy of 86% for distinguishing cancerous tissue 
from normal and benign. Raman spectroscopy has also differentiated between the nuclear 
grades (low, intermediate and high) of ductal carcinoma in situ (DCIS) and invasive ductal 
carcinoma (IDC) of the breast (Rehman et al 2007). This group observed spectral change in 
the intensity of fatty acid chains, phospholipids, cholesterol, proteins and nucleic acids with 
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increasing nuclear grade. It was concluded that high-grade carcinoma tissue is rich in 
acylglyceride while low-grade carcinoma tissue is rich in protein.  
 
More recent work has included surface enhanced spatially offset Raman spectroscopy. 
Stone (Stone et al 2011) recovered for the first time multiplexed surface enhanced Raman 
scattering (SERS) signals noninvasively from a depth of 20 mm in tissues and 
reconstructed these to produce a false colour image. A secondary finding was also that 
Raman signals from SERS nanoparticles could be recovered non-invasively from samples 
of the order of 45–50 mm thick. This was huge step forward in the ability to detect and 
identify vibrational ﬁngerprints within tissue and offered the opportunity to adapt these 
particles and this approach into a clinical setting for disease diagnosis. 
 
4.5 Raman Spectroscopy and lymph nodes 
The use of Raman in the assessment of lymph nodes in breast cancer has hitherto been 
limited, the majority of work being done on the breast itself and other tissues. Assessment 
of Silicone lymphadenopathy appears to be the starting point for its use in analysing lymph 
nodes. In 1993, Frank used Raman spectroscopy to examine lymph node biopsy specimens 
from women with ruptured breast implants containing silicone gel (Frank et al 1993). Since 
silicone has a strong Raman peak, the lymph nodes containing silicone inclusions were 
clearly identified. 
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The first paper to demonstrate Raman mapping of malignant spread in axillary lymph nodes 
was published in 2003 (Smith et al 2003). Tissue was collected after surgical resection for 
breast cancer. A portion of one lymph node from each case was removed and snap frozen. 
The samples were later cut for spectroscopy and for histological assessment, using a 
microtome. Spectra were collected from the lymph node tissue and analysed using Principal 
Component Analysis (PCA).  
 
The spectral maps were compared with white light images of the same section and the 
stained histological slides of parallel sections. The intensity of the principal component 
spectra could thereby be examined for specific lymph node features described by the 
histologist. Additionally, the relative presence of molecules identified in PCA, such as 
lipids, could be assessed in various areas of nodal section. 
The authors emphasized that the long running time required for spectroscopic analysis of 
this nature meant that this detailed mapping was not suitable for real-time clinical use itself. 
However, it was an ideal way to map features common to lymph nodes so that a diagnostic 
model could be created for comparison and prediction of pathology of new samples. 
Further spectra would be required. 
Two years later, a classification model using 59 lymph node sections from breast cancer 
patients demonstrated 91% sensitivity and 93% specificity for correct classification of 
cancerous node spectra (Smith et al 2005).  
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In 2008, Isabelle (Isabelle et al 2008) took lymph node samples removed during 
oesophagectomies for primary cancer. The lymph nodes were cut in half; one half was sent 
for histological analysis; the other half was snap frozen and later underwent both Raman 
and IR spectroscopic analysis. Out of 20 lymph nodes, 11 were malignant and 9 benign. 
The authors demonstrated the biochemical differences between the mean pathological 
spectra of these two groups. Benign lymph nodes had increased lipid and carbohydrate 
concentrations and lower nucleic acid concentrations. The latter is assumed to be due to 
greater mitotic activity in the malignant nodes. The results of the study showed a training 
performance for Raman and IR spectroscopy of >94% for the differentiation between 
benign and malignant tissue. It was however a small study and so further supporting data 
would be needed to strengthen their results. It was also noted that most spectral peaks had 
contributions from more than one biochemical component and so assignment of the peaks 
to specific biochemical changes was often speculative. 
 
4.5.1  Raman spectroscopy probe in the intra-operative assessment of lymph nodes  
Horsnell (Horsnell et al 2010) demonstrated in vitro results of the use of a Raman 
spectroscopy probe to evaluate the status of axillary nodes sampled from patients with 
newly diagnosed breast cancer. 38 axillary nodes were sampled from 20 patients. Half a 
node was sent to histology whilst the other half was snap frozen and later assessed in the 
laboratory with the hand-held Raman probe. Histological assessment demonstrated 25 
nodes to be negative and 13 nodes to be positive. The mean spectra demonstrated evident 
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differences between positive and negative nodes. Principal Component Analysis was 
employed to demonstrate these differences further. The results of the PCA were then used 
to perform linear discriminant analysis which had been trained by the histopathology 
results. The training model achieved a remarkable 97% sensitivity and 99% specificity at 
differentiating the two groups.  
 
Internal validation of these results demonstrated a sensitivity for the method of up to 92% 
and specificity of up to 100% in differentiating normal and metastatic nodes.  
 
Horsnell (Horsnell, 2012), has explored the use of the probe in the theatre setting. Lymph 
node samples were collected from 50 patients undergoing axillary surgery for breast cancer.  
After resection, the nodes were bisected.  Each half was assessed using a portable Raman 
spectroscopy device with a mean assessment time of 138sec. The node was then sent for 
post-operative histopathological assessment as is usual for current breast operations. 
 
Of the 209 lymph node halves, histology classified 181 as negative and 28 as positive. 1507 
spectra were obtained from the negative nodes and 300 from the positive nodes. Principal 
component analysis followed by linear discriminant analysis showed a specificity of 99% 
and a sensitivity of 92% at differentiating between the two groups. However the strength of 
these figures might be questioned given the imbalance in data between the positive and 
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negative groups. Significant differences in the peaks associated with fatty-acids were also 
noted.  
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CHAPTER 5 MATERIALS AND METHODOLOGY 
 
5.1 Ethical approval 
Ethical approval for the project was granted by Gloucestershire Local Ethics Committee. 
Those patients eligible for participation within the study had a diagnosis of breast cancer 
and were due to undergo axillary lymph node surgery as part of their disease management. 
 
All patients were consented pre-operatively either in a pre-admission outpatient clinic or on 
the ward. The risks and benefits were explained to the patient and an information leaflet 
supplied. Only those patients who signed the consent form were included in the study. 
 
5.2 Tissue collection 
Collection of the lymph nodes for intraoperative analysis took place in main theatres at 
Cheltenham General Hospital. 
 
Those patients undergoing sentinel lymph node biopsy have radioactive technetium isotope 
injected around the ipsilateral nipple pre-operatively in the radiology department. 
Lymphoscintigraphy images are taken and triangulated body marking is used to mark 
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where the sentinel lymph node(s) are. Once anaesthetised in theatre, Patent Blue V dye is 
also injected around the nipple.  
 
Following a small axillary incision and careful dissection of the axilla by either the 
consultant surgeon or specialist registrar, the sentinel lymph node(s) is detected with 
assistance from the lymphoscintography images, triangulated skin markings, blue dye and 
handheld gamma probe. The lymph node(s) are excised using sharp dissection with or 
without the use of diathermy. 
 
Those patients undergoing axillary lymph node clearance do not undergo any pre-operative 
procedures. An incision is made in the axillary skin and the whole axilla is carefully 
dissected in order to remove all lymph nodes in the anatomical space. 2 or 3 lymph nodes 
are taken at random from the dissected tissue for spectral collection. 
 
Once removed from the body, the lymph nodes are handed over and taken through to the 
side room away from the operating theatre. Using a scalpel, any fatty tissue is excised 
before the node(s) are carefully bisected. Each half is labelled „a‟ or „b‟ and numbered 
according to the order in which they are excised as well as the gamma probe reading. 
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For example, the first sentinel node is labelled 1a and 1b once bisected; the second sentinel 
node is labelled 2a and 2b, and so on. 
 
Following collection of spectra, as described below, the lymph node halves are placed into 
separate pots of formalin, carefully marked with the patient‟s details, date and lymph node 
number and sent to the histology department, as per protocol. 
 
5.3 Histopathology 
Within the histology laboratory, the specimens are examined macroscopically before being 
processed in cassettes and then put into hot paraffin wax to protect the tissue. Once cooled 
the wax blocks are cut into very thin slices, using a microtome, which are then put onto 
glass slides and undergo H+E and immunohistochemistry staining for microscopic analysis. 
Reporting of the histopathology results is validated by a consultant histopathologist. 
 
The classification used for the lymph nodes is as follows: 
0 Negative lymph node in an axilla with no positive lymph nodes 
1 Negative lymph node in an axilla containing positive lymph nodes 
2 Isolated Tumour cells  
3 Lymph nodes with micrometastases only 
4 Lymph nodes with macrometastases 
5 Fat only (no lymphatic tissue) 
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The timing and accuracy of tissue collection and histopathological analysis are not affected 
by the intra-operative Raman studies in any way. No tissue loss or damage occurs and, 
similarly, no extra tissue is required for the studies. The overall management of the 
patient‟s disease is not altered which is paramount in delivering patient care. 
 
5.4 Tissue Samples  
Tissue samples were collected between July 2011 and February 2012, with 37 patients 
taking part in the study. 27 patients underwent sentinel lymph node biopsy whilst the 
remaining patients underwent axillary clearance. 
 
The primary breast carcinoma for 31 patients was invasive ductal carcinoma and for 2 
patients was invasive lobular carcinoma. Of the remaining 4, there was 1 medullary 
carcinoma, 1 papillary carcinoma, 1 tubular carcinoma and 1 sarcoidosis. 
 
5.5 Raman spectroscopy 
Measurements of Raman spectra from the lymph nodes collected took place in a side room 
in main theatres. In order to comply with laser safety standards, local rules were adhered to: 
 Controlled area and designation of access to the room 
o No windows 
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o Locked door 
o Appropriate signs on the door 
 Protective eyewear for all those in the room 
 Authorised users only gaining access to room 
 Adverse Incident procedure in place 
 
5.5.1 Raman instrumentation and set-up 
The B&WTEKINC MiniRam II Portable Raman Spectrometer was used to measure spectra 
from each lymph node half (Figure 5.1).  
 
Figure 5.1  B&WTEKINC MiniRam II Portable Raman Spectrometer 
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The spectrometer contains a Class 3B diode laser, λ = 785nm, invisible near infrared beam 
with a maximum power output of 350mW and 174mW accessible beam from the probe. 
The laser beam is transmitted down a fibre optic delivery system attached to a probe head 
fitted with a shutter.  
 
The spectrometer is connected to a laptop computer with the appropriate BWSpec
TM 
software installed for data collection as well as control of laser excitation. 
 
The set-up of equipment is based on that created by Horsnell in his recent doctorate lymph 
node studies at Cranfield University, which are, as yet, unpublished and awaiting formal 
assessment. The handheld probe is mounted on a metal clamp stand with the probe facing 
upwards so that the lymph node half can sit on top during measurement of spectra. The 
probe head itself is mounted with a light impermeable case (Figure 5.2). During excitation 
of the laser and spectral collection, a black impermeable sheet is secured over the top of the 
case to prevent any light from entering. 
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Figure 5.2  Set-up of the portable Raman Spectrometer 
 
 
For each patient, a protective disposable sterile probe sheath is used to cover the probe in 
order to prevent cross-contamination between samples as well as to keep the equipment 
clean. 
 
5.5.2 Calibration 
In order to detect fluctuations over time within the spectrometer, spectral measurements are 
performed at the start of every theatre list for Blue Patent V Dye, PTFE, cyclohexane, green 
glass and a plastic pipette tip. The results are calibrated into the end results for the lymph 
nodes during analysis (see Chapter 6). 
57 
 
5.5.3 Measurement of lymph node spectra 
Following bisection of the lymph nodes into halves as detailed above, each half is placed on 
the probe tip and the impermeable case covered with the black sheet. Spectra are measured 
for 16 x 1 sec acquisitions and the average presented graphically. 5 sets of mean spectra are 
taken per lymph node half. As a variation to Horsnell‟s model the lymph node half is in fact 
moved at random between each set so that spectra are taken from 5 areas of the lymph node 
half. 30 seconds between the 16sec acquisitions was given to allow manual manipulation of 
the lymph node. 
 
The rationale behind the above variation is attributed to work done by Smith (Smith 2005) 
who looked at probe models which were designed to mimic the use of a probe on a cut 
lymph node surface. Three models were constructed comparing results from the selection 
of 5, 10 and 20 points on tissue sections. 
Figure 5.3  Diagram showing approximate selection pattern for probe models (Smith 2005) 
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Analysis of results demonstrated that the highest percentage of correctly classified positive 
spectra was achieved in the Probe 20 model (86%). The highest percentage of correctly 
classified negative spectra was achieved in the Probe 10 model (93%), only 3 % higher than 
the Probe 20 model. In general Smith‟s models demonstrated that results for sensitivity and 
specificity were optimised when a greater number of sample blocks were collected from 
each node section. 
 
Movement of the lymph node does indeed increase the time taken for data collection by an 
extra 2 minutes per lymph node half. However, in the clinical setting this is negligible. 
Furthermore a more sophisticated  probe design might incorporate this movement so that 
this time is reduced. 
 
5.6 Spectral Analysis  
Following data processing, multivariate statistical analysis is employed in order to identify 
and quantify differences between spectra. Peak assignments are incorporated in order to 
identify biochemical assignments for spectral peaks. 
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5.6.1 MATLAB 
Initially, for each lymph node half, spectral and histological data is entered into MATLAB 
which is a software programme for algorithm development, data analysis, visualization, and 
numerical computation.  
 
During data processing, prior to analysis, the software was used to clean the data. Spectra 
with an average value greater than 25000 was removed as the CCD saturates at this level 
giving a poor signal. Data with a value less than 2000 produced insufficient signal to noise 
ratio to make a clear decision. This latter figure is arbitrary but arrived at from experience.  
 
Graphs demonstrating Raman shift against intensity were subsequently created giving a 
qualitative visual demonstration of peak differences between the histological groups. 
 
5.6.2 Peak assignments 
The identification of spectral peaks with regards to their specific biochemical properties is 
carried out using previously published data. It should be noted that significant overlap can 
exist between peaks making identification complex. In this study, I have used peak 
assignments from Kendall (Kendall et al 2002). The details of these will be discussed 
further in chapter 6 with the results. 
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5.6.3 Principal Component Analysis (PCA) 
PCA is a variable reduction procedure which extracts relevant information from large 
complex data sets. It is incorporated as a data analysis technique where measurements are 
obtained on a number of observed variables in order to develop a smaller number of 
artificial variables, Principal Components (PCs). The components are produced in order of 
variance so that the first component (PC1) represents the greatest degree of variance over 
the set, followed by PC2, and so on. 
 
By applying PCA to the spectral dataset, each spectrum is allocated a score for each 
principal component which indicates the representation of each component within that 
spectrum. It follows that the sum of each PC multiplied by its score should recreate the 
original spectrum. Examination of each PC allows the identification of biochemical features 
which differ maximally through incorporation of peak assignments. 
ANOVA was applied to the PCs in order to identify the most significant.  
 
5.6.4 Linear Discriminant Analysis (LDA) 
LDA is a supervised multivariate analytical technique which is applied to the Principal 
Components. It is a form of data analysis which further maximises separation between 
groups and minimises variation within groups. The PC scores are used as input giving an 
output of Linear Discriminant score values. 
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5.6.5  Cross validation 
To assess the significance of the results a “leave one out” cross validation test was 
performed due to the small dataset. From this, sensitivity, specificity and overall 
performance could be determined. 
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CHAPTER 6 RESULTS AND DISCUSSION 
 
Data collection took place in the main theatres at Cheltenham General Hospital between 
July 2011 and February 2012. 
 
A total of 37 patients were included in the study, all of which were undergoing either 
axillary lymph node clearance or sentinel lymph node biopsy as part of the management for 
breast cancer.  
 
The number of lymph nodes sampled per patient varied between 1 and 3, giving an average 
of 1.65 and mode of 1 per patient. 
 
6.1 Histopathology 
122 lymph node halves were collected in total. Table 6.1 demonstrates the histopathological 
findings of the lymph node halves where a positive lymph node contains evidence of 
metastases and a negative lymph node does not.  
Six lymph nodes were found to have different histopathological findings in each of their 
halves. Table 6.2 demonstrates the histological variation of these lymph nodes. 
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Table 6.1 Histology of lymph node halves  
HISTOPATHOLOGICAL FINDINGS NO. LYMPH NODE 
HALVES 
Total Negative Lymph Node Halves 87 
Negative in an axilla containing positive lymph nodes 25 
Negative lymph node in an axilla with no positive lymph nodes 62 
Total Positive Lymph Node Halves 30 
Lymph nodes with micrometastases only 2 
Lymph nodes with macrometastases 28 
Fat only ( no lymphatic tissue) 4 
Isolated Tumour cells 1 
TOTAL 122 
 
Table 6.2  Histological variation within lymph nodes 
Lymph node half Histopathological findings 
1a Fat only ( no lymphatic tissue) 
1b Negative 
2a Fat only 
2b Negative 
3a Isolated Tumour Cells 
3b Negative 
4a Micrometastases 
4b Negative 
5a Macrometastases 
5b Negative 
6a Micrometastases 
6b Macrometastases 
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6.2 Raman Spectra 
5 spectra were measured for each lymph node half giving a total of 610 spectra. 
 
The spectral data was entered into MATLAB
®
 software for comparison with the 
histopathological findings and subsequent analysis. 
 
Figure 6.1 demonstrates the spectra from all data collected excluding those spectra which 
have been rejected. The latter includes spectra with either an average value of greater than 
25000, suggesting fluorescence, or less than 2000, suggesting insufficient signal. The 
spectra have been background subtracted with a third order polynomial and normalized by 
adjusting the total area under the curve to equal 1.  
 
Figure 6.2 shows the mean spectra of all the above results with polynomial background 
subtraction, normalisation and smoothing. The values of the significant Raman peaks are 
annotated and correspond to specific bonds within the molecules. Table 6.3 demonstrates 
the possible bonds responsible for these peaks (Kendall et al 2002). 
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Table 6.3 Raman Peak assignments (Kendall 2002) 
Raman 
Shift Value  
(cm-1) 
Nearest 
quoted value 
in literature 
(cm-1) 
Assigned Bond Tissue/substance Author 
873 873 hydroxyproline (C-C) Collagen Nie (1990) 
967 966 Hydroxyapatite 
Desmosine/isodesmosine 
Triple helix vibrations 
Calcified plaque 
Elastin 
Collagen type I, skin dermis 
Clarke (1987) 
Manoharan 
(1996) 
Fendel (1988) 
1072 1072 
1074 
P-O asymmetric stretch 
Triglycerides 
Chicken leg bone 
Adipose - aorta 
Nie (1990) 
Baraga (1992) 
1084 1084 
1085 
Lactic acid 
Phenylalanine(amino acid) 
DL-Lactic acid (C3H6O3)CH3-CHOH-COOH 
Protein 
Pilotto (2001) 
Hartman (1973) 
1130 1130 Lipid 
Trans C-C stretch-
phospholipids 
Human skin 
Human brain tissue, glioma grade III 
Carter (1998) 
Mizuno (1994) 
1180 1180 Tyrosine Breast Manoharan 
(1998) 
1271 1271 Amide III Collagen Mahadevan-
Jansen (1998) 
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1305 1304 
1306 
CH3CH2 twisting 
Lipid 
Oleic acid methyl ester 
Human colon 
Frank (1995) 
Redd (1993) 
1369 1365 
1372 
Guanine, tryptophan 
Lipid 
 
Human colon 
Hartman (1973) 
Redd (1993) 
1446 1445 
 
1447 
CH3CH2 deformation in 
collagen 
CH2 bending mode 
CH3CH2 bending modes 
in bovine albumin 
Sigma Aldrich C7774 
Normal breast tissue 
Sigma Aldrich A2153 
Kendall (2002) 
Manoharan 
(1998) 
Kendall (2002) 
1535 1529 
1540 
Carotenoid 
Amide II 
Normal colon 
Bovine Insulin 
Redd (1993) 
Sajid (1997) 
1660 1660-1670 Amide I (C=O stretch) Unordered protein secondary structure Carey (1982) 
1750 1750 C=O Skin dermis Fendel(1988) 
 
Intensity changes and peak shifts at these points may therefore highlight significant 
differences between histological tissue types thus allowing identification. 
 
Figure 6.3 separates the spectra into the different histological classifications. There is a 
visible difference in peak ratio at 1072:1084 for negative nodes compared with nodes 
containing macrometastases. This represents a possible change in triglyceride to lactic acid 
balance, the positive nodes containing a greater proportion of triglycerides compared to 
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lactic acid. Furthermore, the peak ratio at 1072:1130 is less for positive nodes than negative 
nodes, suggesting a smaller triglyceride to phospholipid ratio. Looking at micrometastases 
compared to macrometastases, the collagen to lipid ratio (1271:1305) is much less for those 
nodes with micrometastases. 
 
Figure 6.4 demonstrates the average spectra collected from lymph node halves reported as 
histologically positive in comparison to those reported as histologically negative. The 
differences mentioned above are re-emphasised. Also of note is the difference in peak ratio 
at 1369:1446, the negative nodes demonstrating a higher proportion of collagen in 
comparison to lipid content. The peak shape at 1535, possibly corresponding to amide II or 
carotenoid, is also visibly different between the two histological groups, suggesting a 
greater concentration in positive nodes. 
 
 Figure 6.5 elicits the spectral difference between these two groups. The most intense 
differences are again reiterated as above. Intensities greater than zero correspond to benign 
nodes whilst those below zero correspond to malignant nodes. 
 
The overlap between peak shapes for the average and standard deviations of both negative 
and positive lymph node halves are manifested in Figure 6.6. Comparing the two figures, 
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there is certainly some visible overlap between the two groups and this will be discussed 
later on in the chapter when considering linear discriminant analysis of the data. 
 
Within the positive lymph node halves, 2 out of 30 were found to have micrometastases 
rather than macrometastases. A difference between the spectra from these two 
classifications is shown in Figure 6.7. For the macrometastases, greater peak intensities are 
seen at 1072 (triglyceride concentration), 1130 (lipid concentration) and 1446 (collagen 
concentration). The peak ratio 1271:1305 (collagen: lipid) is again demonstrated and is 
much less for those nodes with micrometastases. Another difference is the peak shape at 
1180 which represents tyrosine. However, as will be discussed later, with only 2 lymph 
node halves showing micrometastases, the strength of these comparisons are very weak. 
Worthy of note though is the similarity in peak shapes and ratios of the micrometastases to 
benign nodes. This could be a reflection of a higher proportion of normal tissue being 
present and malignant changes not being picked up. More specimens with micrometastases 
would need to be analysed in the future before any conclusion can be made. 
 
Within those lymph node halves reported as negative, 25 out of 87 were sampled from an 
axilla also containing positive lymph nodes. Figure 6.8 demonstrates that there is visually 
very little difference between the spectra for these nodes in comparison with those sampled 
from a negative axilla. 
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6.3 Analysis of results 
The data collected was used to produce various training models. Cross validation via a 
“leave one node out” scenario was used to produce an overall training performance figure 
for both a “6 group” model and “2 group” model. 
 
Principal component analysis was performed for each model to demonstrate the most 
significant spectral peak changes between the histopathological groups. 
 
ANOVA of the principal components demonstrate the components with the most 
significance. A scatter plot of these thus demonstrates the degree of separation, as described 
later on in this chapter. 
 
Application of Linear Discriminant Analysis, through further data reduction, was able to 
demonstrate the degree of separation between groups and variation within groups. An 
example of PCA-fed LDA is demonstrated by Kendall in determining whether Raman 
Spectroscopy can be used to detect dysplastic cells with a higher probability of progression 
to cancer in the oesophagus. ( Kendall et al 2011) 
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6.3.1 The “6 Group” Model 
This model demonstrated the likelihood of correctly predicting in which of the 6 
histopathology groups the node would be found.  
 
In order to further reduce any errors caused by any possible changes to the instrument over 
time, the data was recalibrated using a green glass fluorescent standard.  Although 
normalisation and smoothing still took place, there was no background subtraction on the 
data used in the multivariate analysis described above as it would add in more error. 
 
Figure 6.9 demonstrates the “mean centred spectral data”. This is created through 
subtraction of the mean spectra from the overall data set shown in Figure 6.1. It therefore 
shows the variation in spectral peaks between data. 
 
The principal components (PCs) for this dataset are demonstrated in Figure 6.10. The order 
of PCs demonstrates the areas of largest spectral variation. 
 
Application of ANOVA to the PCs highlights the peak changes shown in PC 6 and 7 as the 
most significant. 
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PC6 highlights peak changes at 1072, 1084, 1272, 1305 and 1446. Using the peak 
assignments from Table 6.3, the data would suggest changes in concentration for 
triglycerides, phenylalanine, amide III, lipid and collagen between the histological groups. 
PC7 further describes changes in amide II (1535) and amide I (1660) concentration. 
 
The reasons behind these varying concentrations are not necessarily clear but various 
research papers can provide support for this finding. Liu (Liu et al, 2012) measured the 
fasting serum lipid profile of 324 breast cancer patients with and without synchronous 
distant metastases. The results of his study demonstrated that hyperlipidaemia is 
significantly associated with distant metastases in breast cancer patients. Similarly, Mbaye 
(Mbaye et al, 2012) showed a 79.3% increase in the rate of phenylalanine in cancerous 
tissues in women with breast cancer. 
 
Proliferation of tumour cells can certainly account for variation in protein concentrations 
and amides. Furthermore, collagen, a major component of connective tissue, supports the 
structure of breast tissue and can also signal to cells.  Normally, collagen is a seemingly 
unorganized mass of curvy threads.  However, a recent study has found that collagen looks 
different at various stages of breast cancer which may account for variation in 
concentration demonstrated here (Conklin et al, 2011). 
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The scatter plot in Figure 6.11 further demonstrates the separation of these six groups. 
Whilst there is considerable overlap between histological types, there is an element of 
separation visible between the benign and malignant histology types.  
The macrometastases have high levels of PC7 which appears to discriminate the positive 
nodes from the negatives. However, the negative nodes in a positive axilla also had 
increased levels of PC7. PC6 though discriminated the macrometastases from these 
negative nodes. 
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6.3.2 The “2 Group” Model 
The “2 group” PC-LDA model is a more simplistic model which is more likely to reflect 
the clinical scenario of “malignant vs. benign”. The training performance for this model is 
very much dependent on the data used for the malignant group and benign group. Predicted 
values are calculated from the Raman classification model. 
For example: 
If the benign group includes: 
 Negative nodes in negative axilla 
 Negative nodes in positive axilla 
 
And the malignant group includes: 
 Macrometastases 
 Micrometastases 
 Isolated tumour cells 
 
 Predicted Benign Predicted Malignant 
Histologically Benign 298 34 
Histologically Malignant 36 81 
 
Overall training performance is 84.4% 
Specificity is 90% 
Sensitivity is 69% 
 
However, the training model can in fact be improved by varying the components of the 
groups. Figure 6.11 demonstrates very few micrometastases and ITC within the results. 
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Furthermore, by inspecting the data, all of the micrometastases data were mispredicted. 
Whilst this is not in itself a valid reason to exclude the results, the tiny amount of spectra 
measured for this group means it has a disproportional effect on the overall results. 
 
The optimal “2 group” model extrapolated from the data is shown below. Nodes containing 
ITC, fat and micrometastases were excluded due to their limited datasets as described 
above. 
Benign group  
 Negative nodes in negative axilla 
 Negative nodes in positive axilla 
 
Malignant group  
 Macrometastases 
 
 
Using this model, the principal components were calculated and ANOVA applied. The 
most significant PCs were once again found to be PC 6 and PC7 (Figure 6.12). The most 
prominent peaks emphasise the same differences in tissue concentration between benign 
and malignant groups as seen in the “6 group” model. 
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Figure 6.13 shows a good separation between the two groups although there is still a 
considerable degree of overlap.  PC7 is developing more spread in the benign group but 
tightening up the malignant group. A plot of PC- LDA demonstrates this further in Figure 
6.14. 
The linear discriminant scores in the malignant group show a wide variation. This is likely 
to be a result of less malignant samples collected in comparison to benign samples (30 vs. 
87 lymph node halves). This imbalance makes comparison of the 2 groups very difficult. 
Cross validation of the datasets produce the following results: 
 Predicted Benign Predicted Malignant 
Histologically Benign 303 29 
Histologically Malignant 30 74 
Overall training performance is 86.4% 
Specificity is 91% 
Sensitivity is 71% 
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6.4 Sources of error 
 
6.4.1 Surgical technique 
Whilst the patients fell under the direct care of either of two consultants, the operations 
were occasionally carried out by surgical registrars under supervision as well as the 
consultants themselves. Fatty tissue around the resected lymph node, number of lymph 
nodes sampled and tissue damage would therefore have varied. In future studies, data 
collection could be limited to one consultant only, although the time taken to collect 
sufficient data would be longer. Alternatively, guidance could be given as to how best to 
harvest the nodes for spectral analysis such as fat removal and limited use of diathermy. 
6.4.2 Probe efficacy 
During the data collection period, the Raman probe (Probe A) broke and therefore failed to 
collect appropriate spectra on one of the collection days. A temporary replacement probe 
(Probe B) was provided before being switched back to the original Probe A once fixed. 
(Table 6.4). Figure 6.15 demonstrates the average spectra for the different probes. There 
does not appear to be any obvious changes with regards to intensity or Raman Shift. 
Table 6.4 Patients affected by Probe changes 
Patient number Probe type 
1-14 Probe A 
15 - 30 Probe B 
31-37 Probe A (fixed) 
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6.4.3 Blue dye 
27 of the patients underwent sentinel lymph node biopsy and thus were injected with Patent 
Blue V dye pre-operatively around the areola of the ipsilateral breast. The remaining 10 
patients underwent axillary node clearance.  
 
Of these 27 patients, only 20 patients had nodes which were visibly blue despite the 
injection. Moreover, the degree of “blueness” varied considerably between samples as well 
as patients. 
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It was noted during collection of data that those lymph nodes with a strong blue colour 
were more likely to emit fluorescent spectra.  
 
The measurement of the concentration of blue dye within each node and the effects on 
spectra collected was beyond the remit of this thesis. However, 2 laboratory based 
experiments were carried out to investigate the following hypotheses: 
1) An increased concentration of blue dye in tissue causes fluorescence. 
4 small cubes of raw chicken were prepared by soaking in the following solutions: 
Chicken Sample Preparation 
Chick 1 Water only 
Chick 2 25% Patent Blue V Dye 
solution 
Chick 3 50% Patent Blue V Dye 
solution 
Chick 4 75% Patent Blue V Dye 
solution 
 
Each cube was then bisected and spectra collected with the handheld Raman Probe, 
using the same method as for the lymph node collection (Chapter 5). 
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Figure 6.16 demonstrates the average spectra for each chicken sample. It shows that an 
increased concentration of blue dye within the tissue elicits an increased fluorescence as 
well as a superimposed „blue dye‟ Raman signal. 
Figure 6.16 Average spectra recorded for each chicken sample 
 
 
Figure 6.17 demonstrates the spectral intensity produced by blue dye alone in 
comparison to that produced by a single lymph node. The difference in intensity is such 
that it demonstrates how spectral measurements of lymph nodes might be skewed by its 
presence. 
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Figure 6.17 Spectral intensity produced by blue dye alone compared to a single lymph node 
 
 
Figure 6.18 demonstrates the mean spectra for lymph nodes resected with visible blue 
dye infiltration compared to those with no visible blue dye. It emphasizes the difference 
in intensity of the signals as discussed previously. It should be noted that any 
significantly fluorescent data would have been rejected as part of the initial results 
analysis. Furthermore, although there appears to be an increase in background signal, 
the Raman peaks associated with the blue dye are not visible in either plot in Figure 
6.18. 
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2) Spectral measurements of blue dye vary according to time exposed to light. 
In order to assess whether spectra could have been related to factors such as exposure of 
blue dye to light once the vile was removed from its box or the length of time the blue 
dye was in the axilla, spectral measurements were taken of blue dye in the laboratory 
setting following varied exposure to light. 
 
 A vial of Patent Blue V dye was opened and pipetted into a sampling tube which was 
then sealed with glue. An initial spectra of the blue dye was collected, following the 
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same method described in Chapter 5. Thereafter spectra were collected at intervals of 
40, 80, 120, 180 and 240 minutes and 23, and 24 hours. In between each set of 
measurements, the sampling tube was exposed to constant light. 
 
No variation was seen in the spectra collected, suggesting that the blue dye was not 
affected by light exposure over the course of 24 hours. 
 
6.4.4 Lymph node size 
The size of the lymph nodes sampled varied considerably within and between patients. It 
was observed that the smaller the lymph node, the weaker the signal which is likely due to a 
reduced volume of tissue to measure. An increased likelihood of fluorescence was also 
noted which may be a result of  an increased dye to tissue ratio, the effects of which are 
noted above. 
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CHAPTER 7 CONCLUSION 
“Ah, but my effect will play a great role for chemistry and molecular structure.” 
C.V Raman 
 
My research described in the preceding chapters has further investigated the role of Raman 
spectroscopy in the intraoperative assessment of lymph nodes in breast cancer management 
through interrogation of the molecular structure of both benign and malignant tissue. The 
work both complements and adds to the work done by Horsnell already (Horsnell et al 
2010, 2012). 
 
The first objective of this study was to assess the use of a hand-held Raman Spectroscopy 
probe in theatre as an accurate, rapid and non-destructive technique for intraoperative 
axillary node assessment. The methodology described in Chapter 5 was simple and could 
easily be followed by the surgeon or an attending non-clinician given the correct training. 
Although the time taken for spectral measurement was not formally recorded, the results 
were available within a reasonable time that would not delay the operation, which would 
otherwise increase anaesthetic time and delay the day‟s operating list. 
 
The accuracy demonstrated by both the “6 group” and “2 group” training models, although 
not quite reaching the “gold standard” of post-operative histological analysis, is still 
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comparative to other techniques currently being researched for the clinical market. Frozen 
section has a similar sensitivity (57-74%) although specificity is far better (99-100%) 
(Layfield et al 2011). Similarly, cytology techniques have a sensitivity of 63% but again a 
far superior specificity rate (Tew et al 2005). Molecular techniques appear to be a better 
option than Raman spectroscopy but cost of set-up and logistics have already removed it 
from the market. According to Horsnell, the Raman probe system would only cost 
approximately £12000 (Horsnell et al 2010). 
 
The other objective addressed in this study was whether the sensitivity of the Raman 
Spectroscopy probe is improved by recording spectra at more than one site on the lymph 
node. Horsnell quoted a sensitivity of up to 92% and a specificity of up to 99% in 
differentiating between normal and metastatic lymph nodes through measuring spectra at 
one single site of the lymph node. However, work done previously by Smith (Smith 2005) 
demonstrated that results for sensitivity and specificity were optimised when a greater 
number of sample blocks were collected from each node section. Unfortunately the “2 
group” training model differentiating benign and metastatic lymph nodes produced both a 
lower specificity (91%) as well as sensitivity (71%). Reasons behind this disappointing 
figure might be multiple. 
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Firstly, due to time restraints and a broken probe, the amount of data collected was far less 
than in Horsnell‟s work. As discussed in Chapter 6, there was also a considerable 
imbalance in benign spectra collected compared with malignant spectra.  
 
The data collection method may also have varied between studies. In Horsnell‟s work it is 
possible that each spectrum was only recorded if it demonstrated a good result, i.e. no 
evidence of poor signal or fluorescence. If the latter was the case then the lymph node 
could have been moved until a reasonable spectrum was achieved. However, the protocol in 
my methodology was perhaps more rigorous in that any spectra seen was recorded, thus 
replicating what would be expected in the clinical scenario. A significant number of spectra 
were therefore rejected prior to analysis, further reducing the pool of results to be analysed. 
 
Furthermore, moving the lymph node at random around the probe, whilst increasing the 
area over which a micrometastasis or ITC might be found, may lead to missing spectra 
from a macrometastasis. Perhaps a more measured and controlled approach may have been 
beneficial. 
 
The role of blue dye in creating increased fluorescence needs to be further investigated. 
However, the laboratory experiments using chicken cubes demonstrated that an increased 
concentration of blue dye within the tissue elicits increased fluorescence as well as 
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superimposed “blue dye” Raman signal. The number of lymph nodes with visible blue dye 
may well have varied between Horsnell‟s work and my own work.  
 
As well as approaching the above issues, the overall accuracy of the probe might be 
improved by development of a higher grade and more robust system. The probe might be 
redesigned so that it is able to sample a greater area of the lymph node to avoid the 
requirement for movement. It might also record a greater number of spectra whilst 
remaining a rapid assessment tool able to cope with the time limits of surgery. Other factors 
which might improve it are a better light source or better wavenumber resolution. 
 
7.1 Future work 
In deciding on future studies for the hand-held Raman Spectroscopy probe in breast cancer 
management, one must also consider where the clinical need lies. As mentioned in Chapter 
1, Giuliano has argued that axillary dissection may not be necessary in all women with 
invasive breast cancer and sentinel node metastasis (Giuliano et al 2011), thus making the 
role of intraoperative lymph node assessment obsolete. However, the axillary nodes still 
need to be assessed and perhaps the role of the hand-held Raman probe as a non-invasive 
technique in the initial assessment clinic should be explored and promoted further.  
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Further work leading from this research may also include the use of a probe for: 
 The assessment of calcifications picked up on mammograms  
 The adequacy of local breast cancer resections with regards to tumour 
margins.  
 Assessment of lymph nodes in lymphoma 
 Assessment of lymph nodes where the primary cancer is unknown 
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APPENDIX A 
A summary of the TNM classification system for breast derived from the AJCC cancer 
staging manual (Edge SB 2010): 
Primary tumour (T)  
TX: Primary tumour cannot be assessed. 
T0: No evidence of primary tumour. 
Tis: Carcinoma in situ (DCIS, LCIS, or Paget disease of the nipple with no associated 
tumour mass) 
T1 (includes T1a, T1b, and T1c): Tumour is 2 cm or less in diameter 
T2: Tumour is between 2 cm and 5 cm in diameter 
T3: Tumour is more than 5 cm in diameter 
T4: Tumour of any size growing into the chest wall or skin. This includes inflammatory 
breast cancer. 
 
Lymph Node (N) 
NX: Nearby lymph nodes cannot be assessed (for example, removed previously). 
N0: Cancer has not spread to nearby lymph nodes.  
 N0 (i+): Tiny amounts of cancer are found in axillary lymph nodes using 
immunohistochemistry. The area of cancer spread contains less than 200 cells and is 
less than 0.2 mm. 
 N0 (mol+): Cancer cells cannot be seen in axillary lymph nodes, but traces of 
cancer cells were detected using PCR. 
N1: Cancer has spread to 1 to 3 axillary lymph node(s), and/or tiny amounts of cancer are 
found in internal mammary lymph nodes on sentinel lymph node biopsy. 
 N1mi: Micrometastases in 1 to 3 axillary lymph nodes.  
 N1a: Macrometastases in 1 to 3 axillary lymph nodes. 
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 N1b: Metastases to internal mammary lymph nodes found specifically during 
sentinel lymph node biopsy but not clinically enlarged. 
 N1c: Both N1a and N1b apply. 
N2: Cancer has spread to 4 to 9 axillary lymph nodes or cancer has enlarged the internal 
mammary lymph nodes (either N2a or N2b, but not both). 
 N2a: Micrometastases to 4 to 9 axillary lymph nodes 
 N2b: Metastases to one or more internal mammary lymph nodes, causing them to 
become enlarged clinically. 
N3: Any of the following: 
 N3a: either 
o Macrometastases to 10 or more axillary lymph nodes OR 
o Macrometastases to the infraclavicular lymph nodes  
 N3b: either: 
o Macrometastases in at least one axillary lymph node with enlargement of the 
internal mammary lymph nodes, OR 
o Macrometastases in 4 or more axillary lymph nodes and metastases in 
internal mammary lymph nodes on sentinel lymph node biopsy. 
 N3c: Macrometastases to the supraclavicular lymph nodes. 
 
Metastasis (M): 
MX: Presence metastasis cannot be assessed. 
M0: No distant spread is found on x-rays (or other imaging procedures) or by physical 
exam. 
 cM0 (i +): Small numbers of cancer cells are found in blood or bone marrow (found 
only by special tests), or micrometastases are found in lymph nodes away from the 
breast. 
M1: Metastatic spread to distant organs is present, the most common sites being bone, 
lung, brain, and liver. 
 
